CR20230485A - Derivados de fósforo como nuevos inhibidores de sos1 - Google Patents
Derivados de fósforo como nuevos inhibidores de sos1Info
- Publication number
- CR20230485A CR20230485A CR20230485A CR20230485A CR20230485A CR 20230485 A CR20230485 A CR 20230485A CR 20230485 A CR20230485 A CR 20230485A CR 20230485 A CR20230485 A CR 20230485A CR 20230485 A CR20230485 A CR 20230485A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- novel
- phosphorus derivatives
- sos1
- sos1 inhibitors
- Prior art date
Links
- 101100421901 Caenorhabditis elegans sos-1 gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003017 phosphorus Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 abstract 1
- 102000057028 SOS1 Human genes 0.000 abstract 1
- 108700022176 SOS1 Proteins 0.000 abstract 1
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 abstract 1
- 101150100839 Sos1 gene Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
- C07F9/65685—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine oxide or thioxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención abarca los derivados de fósforo de la fórmula general (I): (I), en donde R<em>1</em>, R<em>2</em>, R<em>3</em>, R<em>4</em>, R<em>5</em>, R<em>6</em>, X<em>1</em>, X<em>2</em>, X<em>3</em>, X<em>4</em> e Y son como se definen en el presente documento, métodos de preparación de dichos compuestos, compuestos intermedios útiles para la preparación de dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden dichos compuestos y el uso de dichos compuestos para la fabricación de composiciones farmacéuticas para el tratamiento o profilaxis de enfermedades, en particular de trastornos hiperproliferativos, especialmente enfermedades asociadas a SOS1, como agente único o en combinación con otros ingredientes activos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21168256.2A EP4074317A1 (en) | 2021-04-14 | 2021-04-14 | Phosphorus derivatives as novel sos1 inhibitors |
PCT/EP2022/059857 WO2022219035A1 (en) | 2021-04-14 | 2022-04-13 | Phosphorus derivatives as novel sos1 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20230485A true CR20230485A (es) | 2023-12-12 |
Family
ID=75529812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20230485A CR20230485A (es) | 2021-04-14 | 2022-04-13 | Derivados de fósforo como nuevos inhibidores de sos1 |
Country Status (18)
Country | Link |
---|---|
EP (2) | EP4074317A1 (es) |
JP (1) | JP2024513595A (es) |
KR (1) | KR20230170032A (es) |
CN (1) | CN117500507A (es) |
AR (1) | AR125672A1 (es) |
AU (1) | AU2022258751A1 (es) |
BR (1) | BR112023019030A2 (es) |
CA (1) | CA3216503A1 (es) |
CL (1) | CL2023003045A1 (es) |
CO (1) | CO2023013469A2 (es) |
CR (1) | CR20230485A (es) |
DO (1) | DOP2023000218A (es) |
EC (1) | ECSP23077322A (es) |
IL (1) | IL307448A (es) |
MX (1) | MX2023012187A (es) |
PE (1) | PE20240022A1 (es) |
TW (1) | TW202304467A (es) |
WO (1) | WO2022219035A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL298050A (en) * | 2020-05-09 | 2023-01-01 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Phosphorus containing sos1 inhibitor |
CN116425796A (zh) * | 2022-01-12 | 2023-07-14 | 如东凌达生物医药科技有限公司 | 一类嘧啶并杂环类化合物、制备方法和用途 |
WO2024056782A1 (en) * | 2022-09-16 | 2024-03-21 | Bayer Aktiengesellschaft | Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2015A (en) | 1841-03-26 | Improvement in rotary steam-engines | ||
GT198900008A (es) | 1988-01-29 | 1990-07-17 | Derivados de quinolina, quinazolina y cinolina. | |
IL89027A (en) | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Quinazoline derivatives, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them |
PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
US5236925A (en) | 1991-10-24 | 1993-08-17 | American Home Products Corporation | Fused pyrimidines as angiotensin II antagonists |
DE69836427T2 (de) | 1997-08-25 | 2007-09-27 | Bayer Corp. | Heterozyclische ketonen als npy y5 antagonisten |
GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
WO2004058267A1 (en) * | 2002-12-23 | 2004-07-15 | Ariad Pharmaceuticals, Inc. | Heterocycles and uses thereof |
TW200508224A (en) | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
WO2005005382A2 (en) | 2003-07-02 | 2005-01-20 | Cytokinetics, Inc. | Compounds, compositions and methods |
CN1835953A (zh) | 2003-08-15 | 2006-09-20 | 默克专利 | 4-环烷基氨基吡唑并嘧啶nmda/nr2b拮抗剂 |
RU2006142305A (ru) | 2004-04-30 | 2008-06-10 | Такеда Фармасьютикал Компани Лимитед (Jp) | Гетероциклическое амидное соединение и его применение в качестве ингибитора ммр-3 |
SE0401540D0 (sv) | 2004-06-15 | 2004-06-15 | Astrazeneca Ab | New compounds |
ITMI20042042A1 (it) | 2004-10-26 | 2005-01-26 | Pharmeste Srl | Derivati solfonammidici antagonisti del recettore dei vanilloidi trpv1 |
ES2569881T3 (es) | 2005-06-08 | 2016-05-12 | The University Of North Carolina At Chapel Hill | Procedimientos para facilitar la supervivencia de células neuronales usando miméticos de neurotrofina BDNF peptídicos y no peptídicos |
AU2007253513B2 (en) | 2006-05-23 | 2010-07-08 | F. Hoffmann-La Roche Ag | Pyridopyrimidinone derivatives |
AR065718A1 (es) | 2007-03-15 | 2009-06-24 | Novartis Ag | Compuestos heterociclicos nitrogenados,utiles en el diagnostico y tratamiento de trastornos hiperproliferativos. |
JP2008280341A (ja) | 2007-04-12 | 2008-11-20 | Sumitomo Chemical Co Ltd | ヒドラジド化合物およびその防除用途 |
US20090099195A1 (en) | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
FR2929615B1 (fr) | 2008-04-02 | 2010-12-17 | Tfchem | Composes c-aryl glycosides pour le traitement du diabete et de l'obesite. |
WO2009143389A1 (en) | 2008-05-21 | 2009-11-26 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
UA101676C2 (uk) | 2008-07-31 | 2013-04-25 | Дженентек, Инк. | Піримідинові сполуки, композиції і способи застосування |
CN102197033B (zh) | 2008-08-27 | 2014-07-16 | 武田药品工业株式会社 | 吡咯化合物 |
SG173852A1 (en) | 2009-02-27 | 2011-09-29 | Ambit Biosciences Corp | Jak kinase modulating quinazoline derivatives and methods of use thereof |
US8461164B2 (en) | 2009-08-31 | 2013-06-11 | Dow Agrosciences, Llc. | Pteridines and their use as agrochemicals |
DK3575288T3 (da) | 2009-09-03 | 2021-12-20 | Bristol Myers Squibb Co | Quinazoliner som kaliumionkanalinhibitorer |
EP2611789A1 (en) | 2010-09-01 | 2013-07-10 | Ambit Biosciences Corporation | Quinazoline compounds and methods of use thereof |
WO2012030912A1 (en) | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | 7-cyclylquinazoline derivatives and methods of use thereof |
US20120053176A1 (en) | 2010-09-01 | 2012-03-01 | Ambit Biosciences Corp. | Adenosine a3 receptor modulating compounds and methods of use thereof |
RU2013114710A (ru) | 2010-09-03 | 2014-10-10 | Байер Интеллектуэль Проперти Гмбх | Замещенные конденсированные пиримидиноны и дигидропиримидиноны |
US8552200B2 (en) | 2010-10-20 | 2013-10-08 | Gruenenthal Gmbh | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators |
WO2012066122A1 (en) | 2010-11-18 | 2012-05-24 | Syngenta Participations Ag | 2 - (pyridin- 2 -yl) -quinazoline derivatives and their use as microbicides |
UY33775A (es) | 2010-12-10 | 2012-07-31 | Gilead Sciences Inc | Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos |
CN102584828B (zh) | 2011-01-14 | 2016-01-27 | 上海艾力斯医药科技有限公司 | 吡咯烷[3,4-d]嘧啶衍生物、制备方法及其应用 |
WO2012112363A1 (en) | 2011-02-14 | 2012-08-23 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
US8846656B2 (en) | 2011-07-22 | 2014-09-30 | Novartis Ag | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators |
CN102911172A (zh) | 2011-08-04 | 2013-02-06 | 上海恒瑞医药有限公司 | 杂芳基并嘧啶类衍生物、其制备方法和用途 |
KR20140074912A (ko) | 2011-09-01 | 2014-06-18 | 에프. 호프만-라 로슈 아게 | 피롤로피라진 키나아제 억제제 |
CN103387490B (zh) | 2012-05-09 | 2015-08-26 | 中国科学院兰州化学物理研究所 | 一种甲苯羰化合成苯乙酸的方法 |
AU2013270672B2 (en) | 2012-06-08 | 2017-10-19 | Gilead Sciences, Inc. | Macrocyclic inhibitors of flaviviridae viruses |
WO2014100501A1 (en) | 2012-12-20 | 2014-06-26 | Sanford-Burnham Medical Research Institute | Small molecule agonists of neurotensin receptor 1 |
WO2014108406A1 (en) | 2013-01-08 | 2014-07-17 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
CA2908148A1 (en) | 2013-03-29 | 2014-10-02 | Vida Therapeutics, Inc. | Indoline compounds as granzyme b inhibitors |
TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
JP6159028B2 (ja) | 2013-07-31 | 2017-07-05 | ギリアード サイエンシーズ, インコーポレイテッド | Syk阻害剤 |
WO2015155306A1 (en) | 2014-04-11 | 2015-10-15 | Almirall, S.A. | New trpa1 antagonists |
CA2957898C (en) | 2014-09-15 | 2023-02-21 | Rugen Holdings (Cayman) Limited | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists |
SG11201702147TA (en) | 2014-09-17 | 2017-04-27 | Celgene Quanticel Res Inc | Histone demethylase inhibitors |
US20180271869A1 (en) | 2014-09-22 | 2018-09-27 | Jie Liu | Treatment of anxiety disorders and autism spectrum disorders |
CN104803954B (zh) | 2015-04-30 | 2018-01-26 | 上海应用技术学院 | 一种福沙那韦中间体的制备方法 |
US10570098B2 (en) | 2015-07-08 | 2020-02-25 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
WO2017069275A1 (ja) | 2015-10-22 | 2017-04-27 | 田辺三菱製薬株式会社 | 新規二環性複素環化合物 |
GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
WO2018115380A1 (en) | 2016-12-22 | 2018-06-28 | Boehringer Ingelheim International Gmbh | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
GB201700814D0 (en) | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
EP3601267A1 (en) | 2017-03-21 | 2020-02-05 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
FR3066761B1 (fr) | 2017-05-23 | 2020-10-30 | Centre Nat Rech Scient | Nouveaux composes inhibiteurs des canaux ioniques |
MA51290A (fr) | 2017-12-21 | 2021-03-31 | Boehringer Ingelheim Int | Nouvelles pyridopyrimidinones à substitution benzylamino et dérivés à utiliser en tant qu'inhibiteurs de sos1 |
EP3981767A1 (en) | 2018-03-05 | 2022-04-13 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
CN109776607B (zh) | 2019-02-21 | 2021-06-04 | 青岛海洋生物医药研究院 | 芳基磷氧类和芳基磷硫类化合物及其制备方法和应用 |
CN113767100A (zh) | 2019-03-01 | 2021-12-07 | 锐新医药公司 | 双环杂芳基化合物及其用途 |
CN113727758A (zh) | 2019-03-01 | 2021-11-30 | 锐新医药公司 | 双环杂环基化合物及其用途 |
IL298050A (en) | 2020-05-09 | 2023-01-01 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Phosphorus containing sos1 inhibitor |
-
2021
- 2021-04-14 EP EP21168256.2A patent/EP4074317A1/en not_active Ceased
-
2022
- 2022-04-13 BR BR112023019030A patent/BR112023019030A2/pt unknown
- 2022-04-13 KR KR1020237038673A patent/KR20230170032A/ko unknown
- 2022-04-13 PE PE2023002853A patent/PE20240022A1/es unknown
- 2022-04-13 CN CN202280041248.5A patent/CN117500507A/zh active Pending
- 2022-04-13 WO PCT/EP2022/059857 patent/WO2022219035A1/en active Application Filing
- 2022-04-13 AU AU2022258751A patent/AU2022258751A1/en active Pending
- 2022-04-13 CR CR20230485A patent/CR20230485A/es unknown
- 2022-04-13 JP JP2023563038A patent/JP2024513595A/ja active Pending
- 2022-04-13 EP EP22722729.5A patent/EP4322962A1/en active Pending
- 2022-04-13 AR ARP220100954A patent/AR125672A1/es unknown
- 2022-04-13 MX MX2023012187A patent/MX2023012187A/es unknown
- 2022-04-13 CA CA3216503A patent/CA3216503A1/en active Pending
- 2022-04-13 IL IL307448A patent/IL307448A/en unknown
- 2022-04-14 TW TW111114329A patent/TW202304467A/zh unknown
-
2023
- 2023-10-09 DO DO2023000218A patent/DOP2023000218A/es unknown
- 2023-10-11 CO CONC2023/0013469A patent/CO2023013469A2/es unknown
- 2023-10-12 CL CL2023003045A patent/CL2023003045A1/es unknown
- 2023-10-12 EC ECSENADI202377322A patent/ECSP23077322A/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2022219035A1 (en) | 2022-10-20 |
AR125672A1 (es) | 2023-08-02 |
CA3216503A1 (en) | 2022-10-20 |
CL2023003045A1 (es) | 2024-03-22 |
DOP2023000218A (es) | 2023-11-15 |
AU2022258751A1 (en) | 2023-10-05 |
TW202304467A (zh) | 2023-02-01 |
ECSP23077322A (es) | 2023-11-30 |
KR20230170032A (ko) | 2023-12-18 |
CN117500507A (zh) | 2024-02-02 |
PE20240022A1 (es) | 2024-01-04 |
BR112023019030A2 (pt) | 2023-10-24 |
EP4322962A1 (en) | 2024-02-21 |
MX2023012187A (es) | 2023-10-25 |
CO2023013469A2 (es) | 2024-04-29 |
IL307448A (en) | 2023-12-01 |
JP2024513595A (ja) | 2024-03-26 |
EP4074317A1 (en) | 2022-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500932A1 (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
CR20230485A (es) | Derivados de fósforo como nuevos inhibidores de sos1 | |
WO2018077944A3 (en) | 4,5-annulated 1,2,4-triazolones | |
PH12018550173A1 (en) | Pyrazolopyrimidine derivatives | |
PH12020500134A1 (en) | Dihydrooxadiazinones | |
WO2020126968A3 (en) | Urea derivatives for use against proliferative diseases | |
PH12019501846A1 (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
WO2017198341A8 (en) | MACROCYCLIC INDOLE DERIVATIVES | |
MY164730A (en) | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
PH12020500257A1 (en) | Quinoline derivatives for treating infections with helminths | |
MX2020010333A (es) | 2-(morfolin-4-il)-1,7-naftiridinas. | |
CR20220236A (es) | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune | |
MY168413A (en) | Amino-substituted imidazopyridazines | |
MX2019012803A (es) | Nuevos derivados de pirazol biciclicos. | |
TN2017000258A1 (en) | Pyrazolopyridinamines as mknk1 and mknk2 inhibitors | |
PH12020551891A1 (en) | New quinoline derivatives | |
PH12020550494A1 (en) | Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors | |
JOP20220034A1 (ar) | مركبات [1، 2، 4] تريازولو [1، 5-جـ] كوينازولين-5-أمين | |
PH12019500808A1 (en) | Substituted 6-(1h-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof | |
MX2021011979A (es) | Derivados del isocromeno como inhibidores de la fosfoinositida 3-cinasa. | |
TN2013000204A1 (en) | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |